SWOG clinical trial number
SWOG-9303 (INT-0130) (NCCTG-91-46-52)

Phase III Study of Radiation Therapy, Levamisole and 5-Fluorouracil versus 5-Fluorouracil and Levamisole in Selected Patients with Completely Resected Colon Cancer

Closed
Phase
Published
Abbreviated Title
Phase III Study of Radiation Therapy, Levamisole and 5-Fluorouracil versus 5-Fluorouracil and Levamisole in Selected Patients with Completely Resected Colon Cancer
Activated
08/15/1993
Closed
12/17/1996

Research committees

Gastrointestinal Cancer

Publication Information Expand/Collapse

2004

Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of Intergroup protocol 0130

JA Martenson Jr;CG Willett;DJ Sargent;JA Mailliard;JH Donohue;LL Gunderson;CR Thomas Jr;B Fisher;AB Benson;R Myerson;RM Goldberg Journal of Clinical Oncology 22(16):1-7

1999

A phase III study of adjuvant radiation therapy (RT), 5-flouorouracil (5-FU), and levamisole (LEV) vs. 5-FU and LEV in selected patients with resected, high risk colon cancer: Initial results of INT 0130.

J Martenson;C Willett;D. Sargent;J Donohue;R Goldberg;T Wasserman;L Gunderson;R Myerson;P Thomas;B Fisher;A Benson, III Proc of the American Society of Clinical Oncology 18:235a(#904)

Other Clinical Trials

SWOG Clinical Trial Number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
100%
Open
Phase